Caenorhabditis elegans ALG-1 antimorphic mutations uncover functions for Argonaute in microRNA guide strand selection and passenger strand disposal.
MicroRNAs are regulators of gene expression whose functions are critical for normal development and physiology. We have previously characterized mutations in a Caenorhabditis elegans microRNA-specific Argonaute ALG-1 (Argonaute-like gene) that are antimorphic [alg-1(anti)]. alg-1(anti) mutants have dramatically stronger microRNA-related phenotypes than animals with a complete loss of ALG-1. ALG-1(anti) miRISC (microRNA induced silencing complex) fails to undergo a functional transition from microRNA processing to target repression. To better understand this transition, we characterized the small RNA and protein populations associated with ALG-1(anti) complexes in vivo. We extensively characterized proteins associated with wild-type and mutant ALG-1 and found that the mutant ALG-1(anti) protein fails to interact with numerous miRISC cofactors, including proteins known to be necessary for target repression. In addition, alg-1(anti) mutants dramatically overaccumulated microRNA* (passenger) strands, and immunoprecipitated ALG-1(anti) complexes contained nonstoichiometric yields of mature microRNA and microRNA* strands, with some microRNA* strands present in the ALG-1(anti) Argonaute far in excess of the corresponding mature microRNAs. We show complex and microRNA-specific defects in microRNA strand selection and microRNA* strand disposal. For certain microRNAs (for example mir-58), microRNA guide strand selection by ALG-1(anti) appeared normal, but microRNA* strand release was inefficient. For other microRNAs (such as mir-2), both the microRNA and microRNA* strands were selected as guide by ALG-1(anti), indicating a defect in normal specificity of the strand choice. Our results suggest that wild-type ALG-1 complexes recognize structural features of particular microRNAs in the context of conducting the strand selection and microRNA* ejection steps of miRISC maturation.
Program in Molecular Medicine, RNA Therapeutics Institute, University of Massachusetts Medical School, Worcester, MA 01605;
Anna Y
AY
Zinovyeva
Program in Molecular Medicine, RNA Therapeutics Institute, University of Massachusetts Medical School, Worcester, MA 01605;
Isana
I
Veksler-Lublinsky
Department of Biological Chemistry, David Geffen School of Medicine, University of California, Los Angeles, CA 90095.
Ajay A
AA
Vashisht
Department of Biological Chemistry, David Geffen School of Medicine, University of California, Los Angeles, CA 90095.
James A
JA
Wohlschlegel
Program in Molecular Medicine, RNA Therapeutics Institute, University of Massachusetts Medical School, Worcester, MA 01605; ambrosvictor@gmail.com.
Victor R
VR
Ambros
D000818:Animals; D060565:Argonaute Proteins / Q000378:metabolism*; D001483:Base Sequence; D015152:Blotting, Northern; D017173:Caenorhabditis elegans / Q000235:genetics*; D029742:Caenorhabditis elegans Proteins / Q000235:genetics / Q000502:physiology*; D018076:DNA, Complementary / Q000378:metabolism; D015723:Gene Library; D013058:Mass Spectrometry; D035683:MicroRNAs / Q000378:metabolism*; D008969:Molecular Sequence Data; D009154:Mutation; D040901:Proteomics; D016601:RNA-Binding Proteins / Q000235:genetics / Q000502:physiology*; D013816:Thermodynamics
C558782:ALG-1 protein, C elegans; D060565:Argonaute Proteins; D029742:Caenorhabditis elegans Proteins; D018076:DNA, Complementary; D035683:MicroRNAs; D016601:RNA-Binding Proteins
ALG-1; Argonaute; microRNA; microRNA*; passenger